Q-omics provides the consensus-scored LINC01146 profile across patient tissues and cancer cell-line models. LINC01146 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC01146 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC01146 RNA expression shows 17,886 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where LINC01146 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01146 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01146 survival associations across molecular data types. LINC01146 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01146 RNA expression–survival associations across cancer types. High LINC01146 expression shows unfavorable associations in LGG, KIRP, STAD and KIRC, but favorable associations in SKCM and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC01146 RNA expression.
This table summarizes LINC01146 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01146. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01146 shows lower tumor expression in LUSC, LIHC and LUAD and higher tumor expression in KIRC, STAD and COAD. The KIRC box plot shows higher LINC01146 RNA expression in tumor versus normal tissue (log2 FC = +0.505, t-test p < 0.001).
This table shows molecular features associated with LINC01146 in patient tissues and cancer cell lines. In patient samples, LINC01146 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
